<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Better Than Latisse &#187; dermatologic</title>
	<atom:link href="http://betterthanlatisse.com/tag/dermatologic/feed/" rel="self" type="application/rss+xml" />
	<link>http://betterthanlatisse.com</link>
	<description></description>
	<lastBuildDate>Tue, 01 May 2012 10:56:22 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>From Serendipity to Pilot Study and Then Pivotal Trial: Bimatoprost Topical for Eyelash Growth</title>
		<link>http://betterthanlatisse.com/daily-health-news/from-serendipity-to-pilot-study-and-then-pivotal-trial-bimatoprost-topical-for-eyelash-growth/</link>
		<comments>http://betterthanlatisse.com/daily-health-news/from-serendipity-to-pilot-study-and-then-pivotal-trial-bimatoprost-topical-for-eyelash-growth/#comments</comments>
		<pubDate>Thu, 01 Apr 2010 22:00:00 +0000</pubDate>
		<dc:creator>epionebh</dc:creator>
				<category><![CDATA[Daily Health News]]></category>
		<category><![CDATA[allergan]]></category>
		<category><![CDATA[clinical-trial]]></category>
		<category><![CDATA[dermatologic]]></category>
		<category><![CDATA[including-related]]></category>
		<category><![CDATA[latisse]]></category>

		<guid isPermaLink="false">http://174.36.226.2/~betterth/daily-health-news/from-serendipity-to-pilot-study-and-then-pivotal-trial-bimatoprost-topical-for-eyelash-growth/</guid>
		<description><![CDATA[Dr. Cohen has been a consultant and clinical trial investigator for Allergan (including related to Latisse). ]]></description>
			<content:encoded><![CDATA[<p>Dr. Cohen has been a consultant and clinical trial investigator for Allergan (including related to Latisse). </p>
<p>Read the original:<br />
<a target="_blank" href="http://dx.doi.org/10.1111/j.1524-4725.2010.01532.x" title="From Serendipity to Pilot Study and Then Pivotal Trial: Bimatoprost Topical for Eyelash Growth">From Serendipity to Pilot Study and Then Pivotal Trial: Bimatoprost Topical for Eyelash Growth</a></p>
]]></content:encoded>
			<wfw:commentRss>http://betterthanlatisse.com/daily-health-news/from-serendipity-to-pilot-study-and-then-pivotal-trial-bimatoprost-topical-for-eyelash-growth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes</title>
		<link>http://betterthanlatisse.com/daily-health-news/fda-advisory-committee-unanimously-recommends-approval-of-latisse-bimatoprost-solution-0-03-as-a-treatment-for-hypotrichosis-of-eyelashes/</link>
		<comments>http://betterthanlatisse.com/daily-health-news/fda-advisory-committee-unanimously-recommends-approval-of-latisse-bimatoprost-solution-0-03-as-a-treatment-for-hypotrichosis-of-eyelashes/#comments</comments>
		<pubDate>Mon, 08 Dec 2008 11:15:58 +0000</pubDate>
		<dc:creator>epionebh</dc:creator>
				<category><![CDATA[Daily Health News]]></category>
		<category><![CDATA[advisory]]></category>
		<category><![CDATA[allergan]]></category>
		<category><![CDATA[applications]]></category>
		<category><![CDATA[dermatologic]]></category>
		<category><![CDATA[dodac]]></category>
		<category><![CDATA[drugs-advisory]]></category>
		<category><![CDATA[drugs-com]]></category>
		<category><![CDATA[fda]]></category>
		<category><![CDATA[ophthalmic]]></category>
		<category><![CDATA[today-announced]]></category>
		<category><![CDATA[wire]]></category>

		<guid isPermaLink="false">http://174.36.226.2/~betterth/daily-health-news/fda-advisory-committee-unanimously-recommends-approval-of-latisse-bimatoprost-solution-0-03-as-a-treatment-for-hypotrichosis-of-eyelashes/</guid>
		<description><![CDATA[IRVINE, Calif.--(BUSINESS WIRE)--Dec 5, 2008 - Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve Latisse... ]]></description>
			<content:encoded><![CDATA[<p>IRVINE, Calif.&#8211;(BUSINESS WIRE)&#8211;Dec 5, 2008 &#8211; Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve Latisse&#8230; </p>
<p>Original post:<br />
<a target="_blank" href="http://feeds.feedburner.com/~r/Drugscom-NewDrugApplications/~3/478986277/latisse_081208.html" title="FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes">FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes</a></p>
]]></content:encoded>
			<wfw:commentRss>http://betterthanlatisse.com/daily-health-news/fda-advisory-committee-unanimously-recommends-approval-of-latisse-bimatoprost-solution-0-03-as-a-treatment-for-hypotrichosis-of-eyelashes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

